Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

Aasia Ghazi; Anita Trikha; William J. Calhoun

doi:10.1517/14712598.2012.642359

Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

Aasia Ghazi, Anita Trikha, William J. Calhoun

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

116 Scopus citations

Abstract

Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

Original language	English (US)
Pages (from-to)	113-118
Number of pages	6
Journal	Expert Opinion on Biological Therapy
Volume	12
Issue number	1
DOIs	https://doi.org/10.1517/14712598.2012.642359
State	Published - Jan 2012

Keywords

Asthma
Benralizumab
IL-5
IL-5Rα
MEDI-563

ASJC Scopus subject areas

Pharmacology
Clinical Biochemistry
Drug Discovery

Access to Document

10.1517/14712598.2012.642359

Cite this

@article{4018fd39abaf49cf874884b17a21f78c,

title = "Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma",

abstract = "Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.",

keywords = "Asthma, Benralizumab, IL-5, IL-5Rα, MEDI-563",

author = "Aasia Ghazi and Anita Trikha and Calhoun, {William J.}",

note = "Funding Information: This review was conducted at the University of Texas Medical Branch at Galveston supported in part by grant UL1RR029876 from the National Center for Research Resources, National Institutes of Health. A Ghazi and A Trikha contributed equally to this work.",

year = "2012",

month = jan,

doi = "10.1517/14712598.2012.642359",

language = "English (US)",

volume = "12",

pages = "113--118",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

AU - Ghazi, Aasia

AU - Trikha, Anita

AU - Calhoun, William J.

N1 - Funding Information: This review was conducted at the University of Texas Medical Branch at Galveston supported in part by grant UL1RR029876 from the National Center for Research Resources, National Institutes of Health. A Ghazi and A Trikha contributed equally to this work.

PY - 2012/1

Y1 - 2012/1

N2 - Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

AB - Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

KW - Asthma

KW - Benralizumab

KW - IL-5

KW - IL-5Rα

KW - MEDI-563

UR - http://www.scopus.com/inward/record.url?scp=84055199162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055199162&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.642359

DO - 10.1517/14712598.2012.642359

M3 - Review article

C2 - 22136436

AN - SCOPUS:84055199162

SN - 1471-2598

VL - 12

SP - 113

EP - 118

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

IS - 1

ER -

Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this